Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $99.8 million.

  • Arcutis Biotherapeutics' Total Current Liabilities fell 4213.75% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 4213.75%. This contributed to the annual value of $81.0 million for FY2024, which is 7359.43% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Total Current Liabilities is $99.8 million, which was down 4213.75% from $103.9 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Total Current Liabilities' 5-year high stood at $172.4 million during Q3 2024, with a 5-year trough of $13.3 million in Q2 2021.
  • Its 5-year average for Total Current Liabilities is $54.0 million, with a median of $37.8 million in 2022.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Total Current Liabilities soared by 31162.6% in 2024 and then crashed by 4213.75% in 2025.
  • Arcutis Biotherapeutics' Total Current Liabilities (Quarter) stood at $33.3 million in 2021, then rose by 13.45% to $37.8 million in 2022, then grew by 23.44% to $46.7 million in 2023, then soared by 73.59% to $81.0 million in 2024, then grew by 23.15% to $99.8 million in 2025.
  • Its last three reported values are $99.8 million in Q3 2025, $103.9 million for Q2 2025, and $91.1 million during Q1 2025.